Apyx Medical Corporation (NASDAQ:APYX) is on recovery track with 26.91% gain from a 1-year low price of $3.01. The company lost -3.78% to attain the price of $3.82 on 4/12/2019. Throughout the recent session, the prices were hovering between $3.75 and $4.02. These shares are 142.15% off its target price of $9.25 and the current market capitalization stands at $130.68M. The recent change has given its price a -45.38% deficit over SMA 50 and -57.03% deficit over its 52-week high. The stock witnessed -45.82% declines, -53.64% declines and -33.68% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found APYX’s volatility during a week at 6.91% and during a month it has been found around 9.8%.Apyx Medical Corporation (APYX) Top Holders
Institutional investors currently hold around $52 million or 42.6% in APYX stock. Look at its top three institutional owners: Rtw Investments, Lp owns $9.14 million in Apyx Medical Corporation, which represents roughly 6.99% of the company’s market cap and approximately 17.57% of the institutional ownership. Similar statistics are true for the second largest owner, Archon Capital Management Llc, which owns 1,979,710 shares of the stock are valued at $7.56 million. The third largest holder is Vanguard Group Inc, which currently holds $4.92 million worth of this stock and that ownership represents nearly 3.77% of its market capitalization.
At the end of December reporting period, 36 institutional holders increased their position in Apyx Medical Corporation (NASDAQ:APYX) by some 1,444,932 shares, 29 decreased positions by 1,086,676 and 10 held positions by 11,090,467. That puts total institutional holdings at 13,622,075 shares, according to SEC filings. The stock grabbed 19 new institutional investments totaling 656,113 shares while 11 institutional investors sold out their entire positions totaling 469,561 shares.Apyx Medical Corporation (APYX) Analyst Guide
Several analysts have released their opinion on Apyx Medical Corporation (NASDAQ:APYX), with 0 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 4 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation [T1].